Articles From: Bioanalytical Systems to Release Third Quarter Results Friday, October 18, 2013; Conference Call & Webcast Set For 11:00 a.m. EDT to BioCryst to Present at Two Upcoming Investor Conferences


2014/1/14
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will make a presentation at the Tenth Annual Noble Financial Capital Markets Equity Conference on Wednesday, January 22, 2014 at 10:00 a.m. EST in Room 1 at the Club Med in Sandpiper Bay, Florida.
Sign-up for Bioanalytical Systems, Inc. to Present at the 10th Annual Noble Financial Capital Markets Equity Conference Wednesday, January 22, 2014 at 10:00 a.m. EST investment picks
TEL AVIV, Israel , August 20, 2013 /PRNewswire/ -- In a report published on July 29 , Bioassociate reiterated a Buy rating on RedHill Biopharma (NASDAQ: RDHL) (TASE: RDHL), and maintained the ADS price target of $14.9 .
Sign-up for Bioassociate Reiterated PT on RedHill Biopharma Following Q2 Report investment picks
ThingWorx ™ today announced that Biocartis , an innovative molecular diagnostics company, has selected ThingWorx as the Machine-to-Machine (M2M) application platform to power its next-generation remote service offering.
Sign-up for Biocartis Selects ThingWorx for Next-Generation M2M Solution investment picks
2014/3/24
SAN DIEGO, March 24, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC) , a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) and biomarker analysis, today announced that it has appointed Raaj Trivedi as Vice President - Commercial Operations.
Sign-up for Biocept Appoints Commercialization Leader to Implement Global Diagnostic Sales Program investment picks
2014/2/10
SAN DIEGO, Feb.
Sign-up for Biocept, Inc. Announces Closing of Initial Public Offering investment picks
2014/3/5
SAN DIEGO, March 5, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC) , an oncology diagnostics company focused on improving individual patient treatment, announced today that the Company's President and Chief Executive Officer, Michael Nall will be presenting at the 26 th Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
Sign-up for Biocept, Inc. to Present at the 26th Annual ROTH Conference investment picks
2014/1/22
Biocon Ltd., (BIOCON.BO), Asia’s premier biotechnology company, and Advaxis, Inc ., (NASDAQ: ADXS), a leader in developing the next generation of cancer immunotherapies, announced today that they have entered into an exclusive licensing agreement for co-development and commercialization of ADXS-HPV , a novel cancer immunotherapy for the treatment of human papillomavirus (HPV)-associated cervical cancer in women, for India and key emerging markets.
Sign-up for Biocon Collaborates with Advaxis for ‘ADXS-HPV’ A Novel Cancer Immunotherapy investment picks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the prevention of hereditary angioedema (HAE) attacks.
Sign-up for BioCryst Advances Second Generation Oral Plasma Kallikrein Inhibitors for Hereditary Angioedema into Preclinical Development investment picks
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the underwriters of its recent public offering of its common stock have exercised in full their option to purchase an additional 600,000 shares.
Sign-up for BioCryst Announces Full Exercise of over Allotment Option investment picks
2014/3/3
RESEARCH TRIANGLE PARK, N.C., March 3, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the online publication in the journal Nature  of extensive laboratory and nonclinical characterizations of BCX4430 , including efficacy results in animal models of infection with Marburg virus and Ebola virus , two highly virulent pathogens responsible for viral hemorrhagic fever diseases.
Sign-up for BioCryst Announces Nature Publication Demonstrating Efficacy of BCX4430 in a Non-Human Primate Model of Filovirus Infection investment picks
2014/2/25
RESEARCH TRIANGLE PARK, N.C., Feb.
Sign-up for BioCryst Announces Peramivir NDA Acceptance by the FDA investment picks
2013/7/30
BioCryst Pharmaceuticals, Inc. , (NASDAQ:BCRX) today announced that it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering for a total of no more than $20 million in gross proceeds.
Sign-up for BioCryst Announces Proposed Public Offering of Common Stock investment picks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has contracted with BioCryst for the development of BCX4430 as a treatment for Marburg virus disease.
Sign-up for BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases (NIAID) to Develop BCX4430 for the Treatment of Marburg Virus Disease investment picks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults.
Sign-up for BioCryst Files Peramivir NDA for the Treatment of Influenza investment picks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has dosed the first subject in OPuS-1 ( O ral P rophylaxi S-1 ), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE). The OPuS-1 trial will test 400 mg of BCX4161 administered three times daily for 28 days in up to 25 HAE patients who have a high frequency of attacks (≥ 1 per week), in a randomized, placebo-controlled, two-period cross-over design.
Sign-up for BioCryst Initiates OPuS-1: a Phase 2a Clinical Trial of BCX4161 in Patients with Hereditary Angioedema investment picks
2013/7/31
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price to the public of $4.40 per share.
Sign-up for BioCryst Pharmaceuticals Prices Public Offering of Common Stock investment picks
2014/3/1
RESEARCH TRIANGLE PARK, N.C., March 1, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced the presentation of two scientific posters today at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Diego describing phase 1 clinical trial results for BioCryst's potent and selective oral kallikrein inhibitor, BCX4161 , together with details of the Company's plasma kallikrein inhibition assay.
Sign-up for BioCryst Presents BCX4161 Phase 1 Trial and Kallikrein Inhibition Assay Results investment picks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2013.
Sign-up for BioCryst Provides Corporate Update and Reports Second Quarter 2013 Financial Results investment picks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter ended September 30, 2013.
Sign-up for BioCryst Provides Corporate Update and Reports Third Quarter 2013 Financial Results investment picks
2014/2/26
RESEARCH TRIANGLE PARK, N.C., Feb.
Sign-up for BioCryst Reports Fourth Quarter and Full Year 2013 Financial Results investment picks
2014/2/12
RESEARCH TRIANGLE PARK, N.C., Feb.
Sign-up for BioCryst to Announce Fourth Quarter and 2013 Financial Results February 26 investment picks
2013/8/1
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its second quarter 2013 financial results will be released on Thursday, August 8, 2013.
Sign-up for BioCryst to Announce Second Quarter 2013 Financial Results August 8 investment picks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2013 financial results will be released on Tuesday, November 5, 2013.
Sign-up for BioCryst to Announce Third Quarter 2013 Financial Results November 5 investment picks
2014/1/2
RESEARCH TRIANGLE PARK, N.C., Jan.
Sign-up for BioCryst to Present at J.P. Morgan Healthcare Conference investment picks
2013/9/3
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10, 2013 at 11:45 a.m. Eastern Time.
Sign-up for BioCryst to Present at Morgan Stanley Global Healthcare Conference investment picks
2014/2/20
RESEARCH TRIANGLE PARK, N.C., Feb.
Sign-up for BioCryst to Present at Three Upcoming Investor Conferences investment picks
2013/11/20
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the following investor conferences: Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm .
Sign-up for BioCryst to Present at Two Upcoming Investor Conferences investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Bioanalytical Systems to Release Third Quarter Results Friday, October 18, 2013; Conference Call & Webcast Set For 11:00 a.m. EDT to BioCryst to Present at Two Upcoming Investor Conferences
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity